Fulcrum Holders Would Get an Estimated $270 Million Dividend and 5% of Slate Medicines

by Maya Okafor · August 17, 2026

Deals & Listings Reporter, The SmallCap Signal

Fulcrum Therapeutics, the Cambridge, Massachusetts biotech that discontinued its only clinical program in June, said Monday it has agreed to merge with a privately held migraine drug developer that would take over its Nasdaq listing, and to pay an estimated $270.0 million in cash to its own stockholders immediately before the deal closes.

Under the all-stock deal announced in a joint release datelined "CAMBRIDGE, Mass. and RALEIGH, N.C., Aug. 17, 2026," Fulcrum (Nasdaq: FULC) will merge with Slate Medicines. The combined business will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq under the ticker "SLTE." The release states that "the pre-Merger Fulcrum stockholders are expected to own 5.0% of the combined company and the pre-Merger Slate stockholders (inclusive of those investors participating in the pre-closing financing) are expected to own 95.0% of the combined company." The 5.0% is not fixed. The release adds that the percentage "is subject to adjustment based on the amount of Fulcrum's net cash at the closing date," and it does not publish the formula by which that adjustment would be made. Nor does it split the 95% between Slate's existing holders and the investors in the new financing. The transaction, the release says, "has received unanimous support by the Board of Directors of both companies."

The cash is the other half of the structure. In the words of the Aug. 17 release, "Fulcrum is expected to contribute approximately $20.3 million in net cash to the combined entity and pay a cash dividend of an estimated $270.0 million immediately prior to the close of the Merger to pre-merger Fulcrum stockholders." Alongside the merger, the release says, "Slate has secured commitments for an oversubscribed concurrent private placement of $245 million from a syndicate of leading healthcare investors led by Frazier Life Sciences and including participation from Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments, and Mingxin Capital." The release says the combined company's cash balance at closing "is expected to fund Slate's operations into 2029." Closing is expected in the fourth quarter of 2026.

Fulcrum arrived at this point quickly. On Monday, June 1, the company announced it was discontinuing pociredir, its oral fetal-hemoglobin inducer for sickle cell disease, after regulatory feedback. That release says the FDA's "position is informed by pociredir's previously disclosed preclinical malignancy observations and left no viable regulatory path forward for further clinical development of pociredir." Fulcrum had made a mechanistic argument to the agency: it "submitted information to FDA supporting the position that mechanistic differences between EED (pociredir's target) and EZH2 (tazemetostat's target), which perform different biological roles, were relevant to the benefit-risk assessment." The release says the agency "considered this position but concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged." The concern, per the release, stemmed "from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026."

"Following a thorough review of regulatory feedback, the totality of available data, and the implications for a viable regulatory path, we have made the very difficult decision to discontinue development of pociredir. While no new safety signals have been observed to date with pociredir, the FDA raised concerns regarding the potential malignancy risk associated with pociredir's inhibition of the PRC2 complex given the experience with Tazverik that was recently withdrawn from the market," Alex C. Sapir, Fulcrum's president and chief executive, said in the June 1 release. "We arrived at this decision after discussion with the FDA, and despite robust elevations in fetal hemoglobin seen with pociredir and the potential for clinical benefit, we do not see a path forward with pociredir. We know the SCD community has faced many disappointments and setbacks related to innovation for this devastating disease, and we are not only humbled but forever grateful to the SCD warriors, investigators, and broader SCD community who have worked tirelessly alongside Fulcrum to evaluate new treatment options for this devastating disease."

The same June release said that "in connection with this review, Fulcrum has initiated efforts to significantly reduce its operating expenses and preserve capital," and that the company "will explore potential strategic alternatives, including, but not limited to, a merger, acquisition, business combination, or other strategic transactions involving the company or its assets." A Form 8-K covering the May 31 board approval says the restructuring plan "will reduce Fulcrum's workforce by approximately 85%, from 57 full-time employees to 9 full-time employees," that the company "expects to incur aggregate charges of approximately $4.2 million in connection with the restructuring plan, consisting primarily of employee severance, employee benefits and related costs," and that Fulcrum "has engaged Leerink Partners LLC as its financial advisor to assist the Board of Directors in reviewing potential strategic alternatives."

This reporter did not open Fulcrum's second-quarter Form 10-Q on EDGAR. The second-quarter figures here come from a StockTitan page for that filing, and that page is two things at once: a block of reproduced filing text — financial statements, notes, management's discussion, risk factors — sitting beneath StockTitan's own AI-generated summary of it. The distinction matters, so it is drawn here. From the reproduced filing text: 76,285,157 shares of common stock issued and outstanding as of June 30, 2026; cash, cash equivalents and marketable securities of $318,840 thousand, or $318.8 million, at June 30; a second-quarter net loss of $26.2 million; and management's discussion naming "dissolution and liquidation of the company" among the courses it might pursue if no transaction is identified. The $45.1 million net loss for the first half appears in StockTitan's summary rather than in the reproduced statements, though it lines up with the $18.9 million first-quarter loss Fulcrum itself reported on April 27 plus the reproduced second-quarter figure. StockTitan dates the filing to July 30, 2026.

Most of the cash Fulcrum is now distributing was raised over the past year. Its first-quarter release, dated April 27, reported $333.3 million in cash, cash equivalents and marketable securities as of March 31 and said the company "expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund its operating requirements into 2029" — the same year the merged company now says its own cash will reach. Net loss was $18.9 million for the quarter.

Roughly $175 million of that came from a single equity raise. On Wednesday, Dec. 10, 2025, Fulcrum priced an upsized public offering of 11,851,853 shares of common stock at $13.50 apiece plus pre-funded warrants to purchase 1,111,193 shares at $13.499, with gross proceeds "before deducting underwriting discounts and commissions and other offering expenses" expected to be $175.0 million and the deal expected to close on or about Dec. 11. Underwriters held a 30-day option on up to 1,944,456 additional shares. J.P. Morgan, Leerink Partners, Cantor, Oppenheimer & Co. and Truist Securities were book-running managers. The release listed the intended use of proceeds as "working capital and capital expenditures, research and development expenses, including to fund clinical trials, regulatory submissions, commercialization, discovery and additional preclinical research and development of additional product candidates and platform enhancement, general and administrative expenses, and potential acquisitions."

Anyone trying to convert the $270.0 million dividend into a per-share figure should stop at the release. It gives no per-share amount, no record date and no reverse stock split. The number is an estimate measured immediately before a closing that has not happened, and the pool of holders entitled to it will be fixed on a record date that has not been set. The reproduced 10-Q text puts common shares outstanding at 76,285,157 as of June 30 — a count from a different date, attached to a different question, and not a denominator this article is willing to use.

The two deal figures and the June balance-sheet figure are also not directly comparable. The $20.3 million of net cash and the $270.0 million dividend are both estimates for the closing date; the $318.8 million is a June 30 balance of cash, equivalents and marketable securities, struck before another quarter of operating costs, restructuring expenses and transaction fees. Fulcrum has not published a reconciliation between them, and this article does not attempt one.

What pre-merger Fulcrum holders are being asked to approve is a transaction that leaves their side with 5.0% of the resulting company, a percentage that itself moves with where Fulcrum's net cash lands at closing. According to the release, Gregory Oakes will lead the combined company, whose board is to include Peter Kolchinsky, Tim Lohoff, Michael Rome and Mark Hahn. The release says the merger requires approval by the stockholders of each company, the effectiveness of a registration statement to be filed with the SEC to register the securities to be issued in the transaction, and the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Slate is barely six months old as a public-facing company. It launched on Feb. 24, 2026 with a $130 million Series A co-led by RA Capital Management, Forbion and Foresite Capital, with participation from an additional undisclosed biotech investor, according to its launch announcement. The Raleigh, North Carolina company was co-founded by Neil Buckley and RA Capital's Sera Medicines, a biologics-focused accelerator. Gregory Oakes is chief executive, Buckley is president and chief operating officer, and Roger Cady, M.D., is chief medical officer. That launch release identified the lead antibody as SLTE-1009, also known as DS009, licensed from DartsBio Pharmaceuticals (Guangdong), Ltd., and said it was expected to begin Phase 1 trials in mid-2026. Three of the Series A backers — RA Capital, Forbion and Foresite — also appear on the investor list for Monday's $245 million placement.

The pipeline the money is meant to fund is early, and the descriptions below are the release's. Monday's release calls SLTE-1009 "a clinical stage subcutaneous anti-PACAP/VIP monoclonal antibody for the prevention of migraine and other headache disorders," engineered with "half-life extension to enable subcutaneous dosing and potential for quarterly administration." The release says the program "has received clearance to enter Phase 1 clinical trials in Australia and initial pharmacokinetic and safety data is anticipated mid-year 2027." It describes SLTE-2100 as "a bispecific antibody targeting PACAP/VIP and calcitonin gene-related peptide ('CGRP'), currently in lead optimization," adding that the program "is expected to enter clinical trials in the second half of 2027 and is funded through a Phase 2a study in migraine patients." The release also says Slate "is also developing an additional undisclosed program in the migraine space."

"Migraine remains one of the most prevalent and disabling neurological diseases, yet millions of patients continue to be underserved by existing therapies," Oakes said in Monday's release. "This merger and the related financing are expected to provide the resources to advance SLTE-1009, along with the rest of our pipeline, through potentially meaningful clinical milestones."

Sapir framed the transaction as the end of the process he started in June. "Following our evaluation of strategic alternatives, we are pleased to announce this transaction with Slate, which we believe represents the best path forward for our stockholders and a compelling opportunity to participate in the development of a portfolio of next generation migraine therapeutics," he said in the release. Wedbush Securities Inc. is exclusive financial adviser and Cooley LLP is legal counsel to Slate; Leerink Partners is exclusive financial adviser to Fulcrum, with Goodwin Procter LLP as legal counsel.

On the tape, Fulcrum closed Friday, Aug. 14 at $3.74, up 0.81% on the day, according to the quote page at stockanalysis.com, which stamps the price "Aug 14, 2026, 4:00 PM EDT" and shows shares outstanding of 76.30 million and a 52-week range of $2.83 to $15.74. RTTNews, in an item on the merger published at 7:46 a.m. ET on Aug. 17, put the stock at $3.95 in pre-market trading, up 5.62%. This article carries no closing price for Monday's session.

The definitive merger agreement, the proxy and registration statement, and the second-quarter Form 10-Q as filed will carry terms this article has not read, among them the record date and per-share amount of the dividend, the mechanics of the net-cash adjustment to the 5.0%, and any termination fee.